News Legend Biotech names ex-Novartis exec as CEO Cell therapy developer Legend Biotech has named Ingrid Zhang as its new chief executive, ending its search for new leadership.
Oncology Bridging the innovation gap: Scalable cell therapies, adapti... Biotech must build manufacturing and trial models that make cell therapies scalable, accessible & commercially viable.
News J&J takes $2.58bn option to buy in vivo CAR-T firm Sail Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.
News FDA advisors vote no to Capricor's DMD therapy FDA advisors voted that Capricor has not shown efficacy for deramiocel in Duchenne muscular dystrophy, due to altered endpoints in its main trial.
News ASCO26: In vivo CAR-Ts in the spotlight Data at ASCO on in vivo CAR-Ts from Kelonia and Legend add to the excitement about the emerging therapy class in both blood cancers and solid tumours.
Oncology CAR-NK cell therapies for solid tumours: Closing the gap bet... CAR-NK cell therapies are frequently misunderstood, despite growing clinical and preclinical data supporting their potential.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
